41 – 60 of 556
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
(
- Contribution to journal › Article
-
Mark
Clinical recognition of frontotemporal dementia with right anterior temporal predominance : A multicenter retrospective cohort study
2024) In Alzheimer's and Dementia(
- Contribution to journal › Article
-
Mark
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
(
- Contribution to journal › Article
- 2023
-
Mark
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
(
- Contribution to journal › Scientific review
-
Mark
Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
‘Proactive aging’ is a new research approach for a new era
(
- Contribution to journal › Letter
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Polygenic risk of type 2 diabetes is associated with incident vascular dementia : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
(
- Contribution to journal › Article